Value of infliximab (Remicade (R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group

F. Baron, S. Suciu, S. Amadori, P. Muus, H. Zwierzina, C. Denzlinger, M. Delforge, A. Thyss, D Selleslag, K. Indrak, G.J. Ossenkoppele, T.M. de Witte

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)529-533
JournalHaematologica
Volume97
Issue number4
DOIs
Publication statusPublished - 2012

Cite this

Baron, F. ; Suciu, S. ; Amadori, S. ; Muus, P. ; Zwierzina, H. ; Denzlinger, C. ; Delforge, M. ; Thyss, A. ; Selleslag, D ; Indrak, K. ; Ossenkoppele, G.J. ; de Witte, T.M. / Value of infliximab (Remicade (R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group. In: Haematologica. 2012 ; Vol. 97, No. 4. pp. 529-533.
@article{3d4b0eb8a6c64b2f89bbfa889aa4e234,
title = "Value of infliximab (Remicade (R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group",
author = "F. Baron and S. Suciu and S. Amadori and P. Muus and H. Zwierzina and C. Denzlinger and M. Delforge and A. Thyss and D Selleslag and K. Indrak and G.J. Ossenkoppele and {de Witte}, T.M.",
year = "2012",
doi = "10.3324/haematol.2011.044347",
language = "Undefined/Unknown",
volume = "97",
pages = "529--533",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "4",

}

Baron, F, Suciu, S, Amadori, S, Muus, P, Zwierzina, H, Denzlinger, C, Delforge, M, Thyss, A, Selleslag, D, Indrak, K, Ossenkoppele, GJ & de Witte, TM 2012, 'Value of infliximab (Remicade (R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group' Haematologica, vol. 97, no. 4, pp. 529-533. https://doi.org/10.3324/haematol.2011.044347

Value of infliximab (Remicade (R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group. / Baron, F.; Suciu, S.; Amadori, S.; Muus, P.; Zwierzina, H.; Denzlinger, C.; Delforge, M.; Thyss, A.; Selleslag, D; Indrak, K.; Ossenkoppele, G.J.; de Witte, T.M.

In: Haematologica, Vol. 97, No. 4, 2012, p. 529-533.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Value of infliximab (Remicade (R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group

AU - Baron, F.

AU - Suciu, S.

AU - Amadori, S.

AU - Muus, P.

AU - Zwierzina, H.

AU - Denzlinger, C.

AU - Delforge, M.

AU - Thyss, A.

AU - Selleslag, D

AU - Indrak, K.

AU - Ossenkoppele, G.J.

AU - de Witte, T.M.

PY - 2012

Y1 - 2012

U2 - 10.3324/haematol.2011.044347

DO - 10.3324/haematol.2011.044347

M3 - Article

VL - 97

SP - 529

EP - 533

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 4

ER -